VEGFA and ANGPT2 are the targets of anti-angiogenesis therapy, and whether the combined inhibition of ADAM9 with bispecific antibody (A2V CrossMab) against both Ang-2 and VEGF can reduce the morbidity and mortality of lung cancer brain metastasis has not been studied. The gene discussed is VEGFA; the disease is lung carcinoma.